Search Results for "establish"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for establish. Results 371 to 380 of 654 total matches.
Ganciclovir
The Medical Letter on Drugs and Therapeutics • Aug 25, 1989 (Issue 799)
other CMV
infections remains to be established.
THE MEDICAL LETTER (ISSN 1523-2859) is published ...
Ganciclovir sodium (Cytovene - Syntex), a synthetic antiviral nucleoside analog, is now available in the USA for intravenous treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients. CMV retinitis occurs in 20% to 25% of patients with AIDS.
Erythropoietin For Anemia
The Medical Letter on Drugs and Therapeutics • Sep 22, 1989 (Issue 801)
of epoetin for pediatric use or during
pregnancy or lactation has not been established. The drug has caused ...
Production of erythropoietin, a glycoprotein hormone secreted mainly by the kidney, is often low in patients with chronic renal failure (JW Eschbach, Kidney Int, 35:134, 1989). The US Food and Drug Administration recently approved marketing of epoetin alfa (Epogen - Amgen), a recombinant human erythropoietin, for treatment of anemia in such patients. Epoetin is commercially available in Europe as Eprex (Ortho), and Eprex is available from Ortho in the USA on an investigational basis for treatment of anemia related to AIDS. Epogen and Eprex are chemically...
Mefloquine for Malaria
The Medical Letter on Drugs and Therapeutics • Feb 09, 1990 (Issue 811)
has
not been established.
ADVERSE EFFECTS — The adverse effects of mefloquine are dose-related. When seven
healthy ...
Mefloquine hydrochloride (Lariam - Roche), a new antimalarial drug chemically related to quinine, has been approved by the US Food and Drug Administration (FDA) for prevention and treatment of Plasmodium falciparum and P. vivax malaria.
Amlodipine - A New Calcium-Channel Blocker
The Medical Letter on Drugs and Therapeutics • Oct 30, 1992 (Issue 882)
with decreased left ventricular function remains to be
established.
THE MEDICAL LETTER (ISSN 1523-2859 ...
Amlodipine (am loe' di peen) besylate (Norvasc - Pfizer), a dihydropyridine calcium-channel blocker, has been approved by the US Food and Drug Administration for once-daily oral treatment of hypertension, chronic stable angina, and vasospastic (Prinzmetal's) angina.
Nefazodone for Depression
The Medical Letter on Drugs and Therapeutics • Apr 14, 1995 (Issue 946)
with
other antidepressants. Better established drugs are preferred.
The Medical Letter, Vol. 37 (Issue 946) April 14, 1995 ...
Nefazodone (Serzone - Bristol-Myers Squibb) was recently approved by the US Food and Drug Administration for treatment of depression. A phenylpiperazine, nefazodone is chemically related to trazodone (Desyrel, and others).
Cerivastatin for Hypercholesterolemia
The Medical Letter on Drugs and Therapeutics • Jan 16, 1998 (Issue 1018)
heart disease remain to
be established. Lovastatin, pravastatin and simvastatin have been shown ...
Cerivastatin (Baycol - Bayer), a new HMG-CoA reductase inhibitor (or "statin"), has been approved by the FDA for treatment of hypercholesterolemia. Cerivastatin is the sodium salt of a synthetic fluorophenyl pyridinyl-substituted heptanoic acid.
Repaglinide for Type 2 Diabetes Mellitus
The Medical Letter on Drugs and Therapeutics • May 22, 1998 (Issue 1027)
in pregnancy remains to be established.
DOSAGE — Repaglinide is available as 0.5-, 1- and 2-mg unscored ...
Repaglinide (Prandin - Novo Nordisk) is a new oral glucose-lowering agent for treating type 2 diabetes (formerly called non-insulin-dependent diabetes mellitus or NIDDM). It has been approved by the FDA for monotherapy or for use in combination with metformin.
Fenoldopam--A New Drug for Parenteral Treatment of Severe Hypertension
The Medical Letter on Drugs and Therapeutics • May 22, 1998 (Issue 1027)
to be established.
THE MEDICAL LETTER (ISSN 1523-2859) is published and printed in the USA bi-weekly ...
Fenoldopam mesylte (Corlopam - Neurex), a peripheral dopamine-1 (DA1) agonist, has been approved by the FDA for parenteral use in lowering blood pressure. The manufacturer claims that, unlike other parenteral antihypertensive agents, fenoldopam not only lowers blood pressure but also maintains or improves renal function.
Nebulized Budesonide For Asthma in Children
The Medical Letter on Drugs and Therapeutics • Jan 22, 2001 (Issue 1096)
of the drug
delivered by jet nebulizers other than the Pari LC-Plus has not been established. Ultrasonic ...
The FDA has approved a nebulized suspension of the corticosteroid budesonide for maintenance treatment of persistent asthma in children one to eight years old.
Bivalirudin (Angiomax) For Angioplasty
The Medical Letter on Drugs and Therapeutics • Apr 30, 2001 (Issue 1103)
to be established. The dosage of
bivalirudin recommended by the manufacturer may be too high.
THE MEDICAL LETTER ...
Bivalirudin is being promoted as an intravenous (IV) anticoagulant that can be used instead of heparin in patients with unstable angina undergoing coronary angioplasty.